The ANA Q&A: Parkinson's Disease

Dr. Ludy Shih

"I think we can look broadly to research across the neurodegenerative diseases to assess how co-morbid pathologies might influence the rate of progression and the severity of expression of the disease. How does cerebrovascular disease affect PD disease course? How does sarcopenia and sedentary lifestyle affect disease progression, and can they be improved?

The ANA Q&A: Neuro-oncology

This month, the ANA talks with Jerome Graber, MD, MPH, an Associate Professor at the University of Washington who specializes in neuro-oncology. Dr. Graber discusses treatment options that improve quality of life for patients, his work with applications of neuroimaging, and more.